
Anne Marie Sabrina Wehbe
Examiner (ID: 18312)
| Most Active Art Unit | 1633 |
| Art Unit(s) | 1632, 1633, 1634 |
| Total Applications | 1342 |
| Issued Applications | 603 |
| Pending Applications | 239 |
| Abandoned Applications | 542 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18938237
[patent_doc_number] => 20240033376
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-01
[patent_title] => SYSTEMS AND METHODS FOR NUCLEIC ACID EXPRESSION IN VIVO
[patent_app_type] => utility
[patent_app_number] => 18/050389
[patent_app_country] => US
[patent_app_date] => 2022-10-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29362
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18050389
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/050389 | SYSTEMS AND METHODS FOR NUCLEIC ACID EXPRESSION IN VIVO | Oct 26, 2022 | Pending |
Array
(
[id] => 18649834
[patent_doc_number] => 20230295659
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-21
[patent_title] => TARGETING PEPTIDES FOR DIRECTING ADENO-ASSOCIATED VIRUSES (AAVs)
[patent_app_type] => utility
[patent_app_number] => 18/047233
[patent_app_country] => US
[patent_app_date] => 2022-10-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29024
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18047233
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/047233 | TARGETING PEPTIDES FOR DIRECTING ADENO-ASSOCIATED VIRUSES (AAVs) | Oct 16, 2022 | Pending |
Array
(
[id] => 18649834
[patent_doc_number] => 20230295659
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-21
[patent_title] => TARGETING PEPTIDES FOR DIRECTING ADENO-ASSOCIATED VIRUSES (AAVs)
[patent_app_type] => utility
[patent_app_number] => 18/047233
[patent_app_country] => US
[patent_app_date] => 2022-10-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29024
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18047233
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/047233 | TARGETING PEPTIDES FOR DIRECTING ADENO-ASSOCIATED VIRUSES (AAVs) | Oct 16, 2022 | Pending |
Array
(
[id] => 18567405
[patent_doc_number] => 20230257737
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-17
[patent_title] => COMPOSITIONS AND METHODS FOR DIRECTING PROTEINS TO SPECIFIC LOCI IN THE GENOME
[patent_app_type] => utility
[patent_app_number] => 17/822240
[patent_app_country] => US
[patent_app_date] => 2022-08-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34642
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 91
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17822240
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/822240 | COMPOSITIONS AND METHODS FOR DIRECTING PROTEINS TO SPECIFIC LOCI IN THE GENOME | Aug 24, 2022 | Pending |
Array
(
[id] => 18325659
[patent_doc_number] => 20230123787
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-20
[patent_title] => RODENT MODEL OF MOOD DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/818730
[patent_app_country] => US
[patent_app_date] => 2022-08-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19205
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -72
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17818730
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/818730 | RODENT MODEL OF MOOD DISORDERS | Aug 9, 2022 | Abandoned |
Array
(
[id] => 18183177
[patent_doc_number] => 20230043907
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-09
[patent_title] => HUMANIZED TRANSGENIC ANIMAL
[patent_app_type] => utility
[patent_app_number] => 17/816608
[patent_app_country] => US
[patent_app_date] => 2022-08-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16718
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17816608
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/816608 | HUMANIZED TRANSGENIC ANIMAL | Jul 31, 2022 | Pending |
Array
(
[id] => 17988801
[patent_doc_number] => 20220354838
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-10
[patent_title] => TREATMENT AND PREVENTION OF OCULAR NEURODEGENERATIVE DISORDER
[patent_app_type] => utility
[patent_app_number] => 17/862668
[patent_app_country] => US
[patent_app_date] => 2022-07-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23660
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 70
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17862668
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/862668 | Treatment and prevention of ocular neurodegenerative disorder | Jul 11, 2022 | Issued |
Array
(
[id] => 18268934
[patent_doc_number] => 20230090176
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-23
[patent_title] => METHODS FOR ISOLATING, CULTURING, AND GENETICALLY ENGINEERING IMMUNE CELL POPULATIONS FOR ADOPTIVE THERAPY
[patent_app_type] => utility
[patent_app_number] => 17/850875
[patent_app_country] => US
[patent_app_date] => 2022-06-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 46903
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17850875
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/850875 | METHODS FOR ISOLATING, CULTURING, AND GENETICALLY ENGINEERING IMMUNE CELL POPULATIONS FOR ADOPTIVE THERAPY | Jun 26, 2022 | Pending |
Array
(
[id] => 17828418
[patent_doc_number] => 20220265722
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-25
[patent_title] => ENGINEERING AND DELIVERY OF THERAPEUTIC COMPOSITIONS OF FRESHLEY ISOLATED CELLS
[patent_app_type] => utility
[patent_app_number] => 17/744970
[patent_app_country] => US
[patent_app_date] => 2022-05-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14140
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 59
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17744970
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/744970 | ENGINEERING AND DELIVERY OF THERAPEUTIC COMPOSITIONS OF FRESHLEY ISOLATED CELLS | May 15, 2022 | Abandoned |
Array
(
[id] => 20239664
[patent_doc_number] => 12419968
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-09-23
[patent_title] => Gene editing to improve joint function
[patent_app_type] => utility
[patent_app_number] => 17/739955
[patent_app_country] => US
[patent_app_date] => 2022-05-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 13425
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 97
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17739955
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/739955 | Gene editing to improve joint function | May 8, 2022 | Issued |
Array
(
[id] => 20239664
[patent_doc_number] => 12419968
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-09-23
[patent_title] => Gene editing to improve joint function
[patent_app_type] => utility
[patent_app_number] => 17/739955
[patent_app_country] => US
[patent_app_date] => 2022-05-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 13425
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 97
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17739955
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/739955 | Gene editing to improve joint function | May 8, 2022 | Issued |
Array
(
[id] => 18063872
[patent_doc_number] => 20220394959
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-15
[patent_title] => HUMANIZED UNIVERSAL LIGHT CHAIN MICE
[patent_app_type] => utility
[patent_app_number] => 17/734392
[patent_app_country] => US
[patent_app_date] => 2022-05-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 46851
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17734392
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/734392 | HUMANIZED UNIVERSAL LIGHT CHAIN MICE | May 1, 2022 | Pending |
Array
(
[id] => 20212010
[patent_doc_number] => 12408640
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-09-09
[patent_title] => Transgenic animal for producing diversified antibodies that have the same light chain I
[patent_app_type] => utility
[patent_app_number] => 17/728874
[patent_app_country] => US
[patent_app_date] => 2022-04-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 20
[patent_no_of_words] => 8727
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 131
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17728874
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/728874 | Transgenic animal for producing diversified antibodies that have the same light chain I | Apr 24, 2022 | Issued |
Array
(
[id] => 20212010
[patent_doc_number] => 12408640
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-09-09
[patent_title] => Transgenic animal for producing diversified antibodies that have the same light chain I
[patent_app_type] => utility
[patent_app_number] => 17/728874
[patent_app_country] => US
[patent_app_date] => 2022-04-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 20
[patent_no_of_words] => 8727
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 131
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17728874
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/728874 | Transgenic animal for producing diversified antibodies that have the same light chain I | Apr 24, 2022 | Issued |
Array
(
[id] => 17805842
[patent_doc_number] => 20220257677
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-18
[patent_title] => ENGINEERED ADENO-ASSOCIATED VIRUS CAPSIDS
[patent_app_type] => utility
[patent_app_number] => 17/707951
[patent_app_country] => US
[patent_app_date] => 2022-03-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 92949
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17707951
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/707951 | ENGINEERED ADENO-ASSOCIATED VIRUS CAPSIDS | Mar 29, 2022 | Pending |
Array
(
[id] => 20413071
[patent_doc_number] => 12496333
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-12-16
[patent_title] => Vaccine compositions comprising C-C motif chemokine 22 (CCL22) or fragments thereof
[patent_app_type] => utility
[patent_app_number] => 17/697623
[patent_app_country] => US
[patent_app_date] => 2022-03-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 32
[patent_figures_cnt] => 35
[patent_no_of_words] => 25832
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 66
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17697623
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/697623 | VACCINE COMPOSITIONS COMPRISING C-C MOTIF CHEMOKINE 22 (CCL22) OR FRAGMENTS THEREOF | Mar 16, 2022 | Issued |
Array
(
[id] => 20413071
[patent_doc_number] => 12496333
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-12-16
[patent_title] => Vaccine compositions comprising C-C motif chemokine 22 (CCL22) or fragments thereof
[patent_app_type] => utility
[patent_app_number] => 17/697623
[patent_app_country] => US
[patent_app_date] => 2022-03-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 32
[patent_figures_cnt] => 35
[patent_no_of_words] => 25832
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 66
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17697623
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/697623 | VACCINE COMPOSITIONS COMPRISING C-C MOTIF CHEMOKINE 22 (CCL22) OR FRAGMENTS THEREOF | Mar 16, 2022 | Issued |
Array
(
[id] => 17807445
[patent_doc_number] => 20220259280
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-18
[patent_title] => BACILLUS THURINGIENSIS TOXIN RECEPTORS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/669839
[patent_app_country] => US
[patent_app_date] => 2022-02-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10531
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17669839
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/669839 | BACILLUS THURINGIENSIS TOXIN RECEPTORS AND USES THEREOF | Feb 10, 2022 | Pending |
Array
(
[id] => 17657107
[patent_doc_number] => 20220177572
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-09
[patent_title] => RESTRICTED IMMUNOGLOBULIN HEAVY CHAIN MICE
[patent_app_type] => utility
[patent_app_number] => 17/579185
[patent_app_country] => US
[patent_app_date] => 2022-01-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28445
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17579185
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/579185 | RESTRICTED IMMUNOGLOBULIN HEAVY CHAIN MICE | Jan 18, 2022 | Pending |
Array
(
[id] => 17719039
[patent_doc_number] => 20220211758
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-07
[patent_title] => AFFINITY MATURATED T CELL RECEPTORS AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/574626
[patent_app_country] => US
[patent_app_date] => 2022-01-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21179
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17574626
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/574626 | AFFINITY MATURATED T CELL RECEPTORS AND USE THEREOF | Jan 12, 2022 | Abandoned |